 | Up a level |
2019
Doerner, T., Schulze-Koops, H., Burmester, G. -R., Iking-Konert, C., Schmalzing, M., Engel, A., Kaestner, P., Kellner, H., Kurthen, R., Krueger, K., Rubbert-Roth, A., Schwenke, H., Peters, M. A. and Tony, H. -P. (2019). Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin. Exp. Rheumatol., 37 (6). S. 937 - 946. PISA: CLINICAL & EXPER RHEUMATOLOGY. ISSN 1593-098X
2016
Behrens, F., Rossmanith, T., Kohm, M., Alten, R., Aringer, M., Backhaus, M., Baerwald, C., Burmester, G., Feist, E., Kellner, H., Krger, K., Muller-Ladner, U., Rubbert-Roth, A., Tony, H. -P., Wassenberg, S. and Burkhardt, H. (2016). RITUXIMAB IN COMBINATION WITH LEFLUNOMIDE: RESULTS FROM A MULTICENTER RANDOMIZED PLACEBO CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL IN ACTIVE RHEUMATOID ARTHRITIS (AMARA-STUDY). Ann. Rheum. Dis., 75. S. 502 - 503. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2060
2011
Kalden, J., Burkhardt, H., Buss, B., Donhauser-Gruber, U., Erstling, U., Gromnica-Ihle, E., Karberg, K., Karger, T., Kneitz, Ch., Krause, A., Krueger, K., Lorenz, H-M., Mueller-Ladner, U., Rubbert-Roth, A., Steffens-Korbanka, P., Tony, H. -P., Wendler, J., Wollenhaupt, J. and Burmester, G. (2011). Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis. Z. Rheumatol., 70 (8). S. 641 - 650. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1435-1250